For an adult with symptomatic knee osteoarthritis who has failed weight control, activity modification, physical therapy, and NSAIDs and has no joint infection or bleeding disorder, how should platelet‑rich plasma (PRP) injections be administered (preparation, dosage, schedule, post‑procedure care) and what defines a successful outcome versus when to consider alternative treatments?

PRP Injections for Knee Osteoarthritis

PRP injections should be considered only after failure of corticosteroid injections in patients with mild-to-moderate knee osteoarthritis (Kellgren-Lawrence grades I-III), but should be avoided entirely in severe disease (KL grade IV) where evidence shows poor treatment response. 1, 2, 3

Guideline-Based Treatment Algorithm

When PRP is Appropriate

• Use PRP only as second-line injectable therapy after intra-articular corticosteroids have failed to provide adequate relief (typically after 3 months) 1, 2
• Restrict to mild-to-moderate disease (KL grades 0-III); the AAOS identifies this as the only appropriate radiographic severity range based on high-quality evidence 1, 2, 3
• Age restriction: Consider only in patients ≤80 years old, as consensus data show appropriateness in this age range 3
• Require documented failure of conservative non-injective treatments including NSAIDs, acetaminophen, physical therapy, weight loss, and exercise programs 1, 2, 4

When PRP is Inappropriate

• Do not use as first-line injectable treatment—corticosteroids possess the strongest evidence base and should be tried first 1, 2
• Avoid in severe osteoarthritis (KL grade IV), where PRP demonstrates significantly worse treatment response 1, 2, 3
• Do not use as initial treatment before attempting conservative measures; 91.7% of expert consensus scenarios rated this as uncertain or inappropriate 3

PRP Preparation and Administration Protocol

Preparation Specifications

• Leukocyte-poor PRP is preferred over leukocyte-rich formulations, as both produce equivalent clinical outcomes but leukocyte-poor PRP shows fewer adverse events (4.7% vs 12.2% mild reactions) 5
• Target platelet concentration: 10 billion platelets total (approximately 1,000-1,200,000 platelets/µL) is critical for sustained chondroprotective effect up to one year 6, 7
• Anticoagulant: Use trisodium citrate, ACD, or CPD; avoid EDTA as it causes platelet swelling and activation 8
• Filtration step: Incorporate 1 µm filtration during manual preparation to improve platelet recovery up to 90% 6

Dosing and Injection Schedule

• Standard regimen: Three weekly intra-articular injections of 5 mL each 6, 5
• Alternative: Single-dose regimens show efficacy in younger patients (<60 years) per AAOS subgroup analysis 1
• Timing: Administer injections at 7-day intervals to allow for biological response between doses 6, 5

Post-Procedure Care

• Immediate: Patients should expect transient injection-site pain or swelling in approximately 4.7-12.2% of cases, typically resolving within days 5
• Activity modification: No specific restrictions are mandated in the evidence, though avoiding high-impact activities for 24-48 hours is reasonable clinical practice
• Concurrent therapy: Continue exercise and weight management programs, as PRP combined with exercise does not outperform exercise alone but both should be maintained 9

Expected Outcomes and Success Criteria

Defining Treatment Success

• Pain relief: Expect mean reduction of 2-4 points on 11-point numeric rating scale at 6-12 months in responders 1, 6, 7
• Functional improvement: WOMAC score improvement of 7-26 points at 12 months, with high-platelet PRP showing clinically significant benefit exceeding MCID of 6.4 points 6, 7
• Duration of benefit: Clinical improvement peaks at 3-6 months and may persist up to 12 months with high-platelet formulations 6, 7
• Inflammatory markers: Successful treatment correlates with significant decline in IL-6 and TNF-α levels at 1 month 6

Treatment Failure Indicators

• No pain improvement of at least 2 points on numeric rating scale by 3 months suggests treatment failure 9, 10
• Lack of functional gain: Failure to achieve WOMAC improvement of ≥6.4 points by 6 months indicates non-response 7
• Severe disease progression: Patients with KL grade IV at baseline show poor response and should not receive PRP 1, 2, 3

When to Consider Alternative Treatments

Immediate Alternatives After PRP Failure

• Repeat corticosteroid injection for acute flares with effusion, as these provide large short-term analgesic benefit (effect size 1.27 over 7 days) 4
• Hyaluronic acid is NOT recommended as an alternative—AAOS recommends against routine use based on 17 high-quality and 11 moderate-quality studies showing inconsistent efficacy (NNT ≈17) 1, 2

Surgical Referral Criteria

• Consider total knee arthroplasty when refractory pain and disability persist despite exhausting all conservative and injectable options 4
• Do NOT refer for arthroscopic surgery—AAOS explicitly recommends against this as it demonstrates no benefit in knee osteoarthritis 4
• Timing: Surgical consultation is appropriate when functional limitations severely impact quality of life despite 6-12 months of comprehensive non-surgical management 4

Critical Caveats and Pitfalls

Evidence Limitations

• Guideline discordance exists: The American College of Rheumatology strongly recommends AGAINST PRP due to lack of standardization and unclear benefit-to-risk ratio, while AAOS gives a "Limited" recommendation emphasizing substantial clinical judgment 2
• Placebo-controlled trials show inconsistency: The high-quality RESTORE trial (n=288) found no significant difference between PRP and saline placebo at 12 months for pain (-0.4 points, 95% CI -0.9 to 0.2) or cartilage volume (-0.2%, 95% CI -1.9% to 1.5%) 10
• GRADE certainty is moderate: Overall evidence quality is limited by heterogeneity in PRP formulations, injection regimens, and follow-up durations 11

Cost and Access Considerations

• Insurance typically does not cover PRP, representing significant out-of-pocket expense with questionable cost-benefit ratio given limited and inconsistent evidence 2
• Cost-effectiveness: The number needed to treat and substantial expense make PRP less favorable compared to corticosteroids or exercise therapy 2

Patient Selection Errors to Avoid

• Do not offer PRP to patients >80 years old—consensus data show this falls outside appropriate age range 3
• Do not skip corticosteroid trial first—PRP should never be first-line injectable therapy 1, 2
• Do not use in patellofemoral-only disease without tibiofemoral involvement—evidence base focuses on tibiofemoral compartment 3
• Do not promise structural disease modification—while preliminary data suggest potential structural-modifying properties, this remains unproven and requires further standardized trials 4